|
|
| | Tat-NR2Baa Basic information |
| Product Name: | Tat-NR2Baa | | Synonyms: | Tat-NR2Baa;L-Alanine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-α-glutamyl-L-alanyl-L-α-aspartyl- | | CAS: | 847829-41-8 | | MF: | C103H184N42O29 | | MW: | 2474.87 | | EINECS: | | | Product Categories: | | | Mol File: | 847829-41-8.mol |  |
| | Tat-NR2Baa Chemical Properties |
| density | 1.52±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | color | White to off-white | | Sequence | Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu-Ala-Asp-Ala |
| | Tat-NR2Baa Usage And Synthesis |
| Uses | Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95[1][2]. | | IC 50 | NMDA Receptor | | References | [1] Michelle Aarts, et al. Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions. Science DOI:10.1126/science.1072873 |
| | Tat-NR2Baa Preparation Products And Raw materials |
|